More about the "ARB MI paradox".
"Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease"
Hall
Alistair S
AS
Strauss
Martin H
MH
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004334:Drug Administration Schedule; D006801:Humans; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced / Q000517:prevention & control*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents
N Engl J Med. 2003 Nov 13;349(20):1963-5
14610159
N Engl J Med. 2003 Nov 13;349(20):1893-906
14610160
Lancet. 2004 Jun 19;363(9426):2022-31
15207952
Lancet. 2004 Jun 19;363(9426):2049-51
15207957
Blood Press. 1998 May;7(3):176-83
9758088
Circulation. 1999 Sep 7;100(10):1056-64
10477530
J Hypertens. 2007 May;25(5):951-8
17414657
Stroke. 2005 Jun;36(6):1218-26
15879332
Hypertension. 2005 Aug;46(2):386-92
16009786
J Hypertens. 2006 Aug;24(8):1679-81; author reply 1681-2
16877973
Circulation. 2006 Aug 22;114(8):838-54
16923768
Circulation. 2006 Aug 22;114(8):855-60
16923769
J Hypertens. 2004 Dec;22(12):2265-6
15614017